CA3006081A1 - Solid forms of (r)-6-(2-fluorophenyl)-n-(3-(2-(2-methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride - Google Patents

Solid forms of (r)-6-(2-fluorophenyl)-n-(3-(2-(2-methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride Download PDF

Info

Publication number
CA3006081A1
CA3006081A1 CA3006081A CA3006081A CA3006081A1 CA 3006081 A1 CA3006081 A1 CA 3006081A1 CA 3006081 A CA3006081 A CA 3006081A CA 3006081 A CA3006081 A CA 3006081A CA 3006081 A1 CA3006081 A1 CA 3006081A1
Authority
CA
Canada
Prior art keywords
approximately
ray powder
powder diffraction
compound
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3006081A
Other languages
English (en)
French (fr)
Inventor
Craig Bates
David P. Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CA3006081A1 publication Critical patent/CA3006081A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3006081A 2015-12-17 2016-12-16 Solid forms of (r)-6-(2-fluorophenyl)-n-(3-(2-(2-methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride Pending CA3006081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268747P 2015-12-17 2015-12-17
US62/268,747 2015-12-17
PCT/US2016/067164 WO2017106642A1 (en) 2015-12-17 2016-12-16 Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds

Publications (1)

Publication Number Publication Date
CA3006081A1 true CA3006081A1 (en) 2017-06-22

Family

ID=59057612

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3006081A Pending CA3006081A1 (en) 2015-12-17 2016-12-16 Solid forms of (r)-6-(2-fluorophenyl)-n-(3-(2-(2-methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride

Country Status (19)

Country Link
US (3) US9981921B2 (enExample)
EP (2) EP3390369B1 (enExample)
JP (2) JP2018537499A (enExample)
KR (1) KR20180086508A (enExample)
CN (1) CN108368061A (enExample)
AU (2) AU2016369523B2 (enExample)
BR (1) BR112018012095A2 (enExample)
CA (1) CA3006081A1 (enExample)
EA (2) EA036295B1 (enExample)
ES (1) ES2935818T3 (enExample)
HK (1) HK1256825A1 (enExample)
IL (1) IL259556B2 (enExample)
MX (2) MX394320B (enExample)
NZ (1) NZ742695A (enExample)
PH (2) PH12018501246A1 (enExample)
SA (1) SA518391805B1 (enExample)
SG (1) SG11201804670PA (enExample)
TW (2) TWI771280B (enExample)
WO (1) WO2017106642A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106639A1 (en) 2015-12-17 2017-06-22 Arqule, Inc. Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
TWI771280B (zh) 2015-12-17 2022-07-21 美商亞闊股份有限公司 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
JP7641247B2 (ja) 2022-03-02 2025-03-06 日立建機株式会社 機械の性能診断装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
EP1638937B1 (en) * 2003-06-18 2008-12-17 Teva Pharmaceutical Industries Limited Fluvastatin sodium crystal form xiv, processes for preparing it, compositions containing it and methods of using it
EP2079736B1 (en) * 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
MX2011006959A (es) * 2008-12-30 2011-12-06 Arqule Inc Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
KR20130105675A (ko) * 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
US9802954B2 (en) * 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
EP2760859A1 (en) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Crystalline forms of azilsartan and preparation and uses thereof
TWI771280B (zh) * 2015-12-17 2022-07-21 美商亞闊股份有限公司 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
WO2017106639A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
US9847831B2 (en) 2016-04-08 2017-12-19 Ciena Corporation Dual wavelenth optical time domain reflectometer systems and methods embedded in a WDM system

Also Published As

Publication number Publication date
PH12018501246A1 (en) 2019-02-04
JP2018537499A (ja) 2018-12-20
EA202091691A1 (ru) 2021-01-29
US10227311B2 (en) 2019-03-12
AU2022201947B2 (en) 2023-07-27
SA518391805B1 (ar) 2022-12-21
WO2017106642A1 (en) 2017-06-22
MX394320B (es) 2025-03-24
TWI771280B (zh) 2022-07-21
HK1256825A1 (zh) 2019-10-04
EP3390369B1 (en) 2022-11-02
EP3390369A4 (en) 2019-08-14
US20200002293A1 (en) 2020-01-02
TWI796250B (zh) 2023-03-11
EA036295B1 (ru) 2020-10-22
US9981921B2 (en) 2018-05-29
PH12020551465A1 (en) 2021-07-26
TW202241854A (zh) 2022-11-01
KR20180086508A (ko) 2018-07-31
US20170174636A1 (en) 2017-06-22
AU2016369523B2 (en) 2021-12-23
EP4019499A1 (en) 2022-06-29
EA201891430A1 (ru) 2018-11-30
US10717710B2 (en) 2020-07-21
ES2935818T3 (es) 2023-03-10
NZ742695A (en) 2022-10-28
CN108368061A (zh) 2018-08-03
JP2022031797A (ja) 2022-02-22
AU2016369523A1 (en) 2018-06-07
MX2018007414A (es) 2018-11-09
MX2021000432A (es) 2022-07-28
US20180258055A1 (en) 2018-09-13
BR112018012095A2 (pt) 2018-11-27
AU2022201947A1 (en) 2022-04-14
SG11201804670PA (en) 2018-07-30
IL259556A (en) 2018-07-31
MX385671B (es) 2025-03-18
IL259556B1 (en) 2023-05-01
EP3390369A1 (en) 2018-10-24
IL259556B2 (en) 2023-09-01
TW201736352A (zh) 2017-10-16

Similar Documents

Publication Publication Date Title
AU2022201947B2 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
AU2023201010A1 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
TWI820182B (zh) 四氫哌喃基胺基－吡咯并嘧啶酮化合物的固體形式
AU2019206118B2 (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
HK40079038A (en) Method of preparing solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
EA044678B1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ СОЕДИНЕНИЯ ДИГИДРОХЛОРИДА (R)-6-(2-ФТОРФЕНИЛ)-N-(3-(2-(2-МЕТОКСИЭТИЛАМИНО)ЭТИЛ)ФЕНИЛ)-5,6-ДИГИДРОБЕНЗО[h]ХИНАЗОЛИН-2-АМИНА
HK1234747A1 (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213